Biotech R&D, Reform, and Market Change
HEHS-95-34R: Published: Dec 15, 1994. Publicly Released: Dec 15, 1994.
Additional Materials:
- Full Report:
Contact:
Pursuant to a congressional request, GAO reviewed the current state of biotechnology financing, focusing on the potential impact of health care reform on the biotechnology sector. GAO noted that: (1) biotech firms are typically small, have few if any products on the market, and are heavily dependent on outside financing for continued operations; (2) biotech firms are facing a cash crunch because investors have been reluctant to invest in biotech products due to disappointing clinical trials for once-promising biotech products; (3) investors have raised questions on how patent laws and health care reform will affect the future profitability of biotech firms; (4) in response to reduced resources, biotech firms have developed alliances with the pharmaceutical industry to provide additional financial and technical support; (5) legislation affecting the prescription drug market may affect the biotech industry directly and indirectly; and (6) if comprehensive health care reform legislation is enacted, the revenues from and demand for prescription drug products could increase or decrease depending on what cost controls are implemented.
Jan 21, 2021
Rural Hospital Closures:
Affected Residents Had Reduced Access to Health Care ServicesGAO-21-93: Published: Dec 22, 2020. Publicly Released: Jan 21, 2021.-
Health Care Funding:
Federal Obligations to and Funds Received by Certain Organizations Involved in Health-Related Services, 2016 through 2018GAO-21-188R: Published: Dec 21, 2020. Publicly Released: Jan 21, 2021.
Jan 14, 2021
-
Medicaid:
Data Completeness and Accuracy Have Improved, Though Not All Standards Have Been MetGAO-21-196: Published: Jan 14, 2021. Publicly Released: Jan 14, 2021.
Jan 4, 2021
-
Medicare Severe Wound Care:
Spending Declines May Reflect Site of Care Changes; Limited Information Is Available on QualityGAO-21-92: Published: Jan 4, 2021. Publicly Released: Jan 4, 2021.
Dec 22, 2020
-
Defense Health Care:
Efforts to Ensure Beneficiaries Access Specialty Care and Receive Timely and Effective CareGAO-21-143: Published: Dec 22, 2020. Publicly Released: Dec 22, 2020.
Dec 16, 2020
-
Medicaid Long-Term Services and Supports:
Access and Quality Problems in Managed Care Demand Improved OversightGAO-21-49: Published: Nov 16, 2020. Publicly Released: Dec 16, 2020.
Dec 14, 2020
-
Drug Pricing Program:
HHS Uses Multiple Mechanisms to Help Ensure Compliance with 340B RequirementsGAO-21-107: Published: Dec 14, 2020. Publicly Released: Dec 14, 2020. -
Substance Use Disorder:
Reliable Data Needed for Substance Abuse Prevention and Treatment Block Grant ProgramGAO-21-58: Published: Dec 14, 2020. Publicly Released: Dec 14, 2020.
Dec 10, 2020
-
Indian Health Service:
Actions Needed to Improve Oversight of Provider Misconduct and Substandard PerformanceGAO-21-97: Published: Dec 10, 2020. Publicly Released: Dec 10, 2020. -
Clinical Labs:
Studies Suggest Biopsy Specimen Misidentification and Contamination Errors Are InfrequentGAO-21-59: Published: Nov 10, 2020. Publicly Released: Dec 10, 2020.
Looking for more? Browse all our products here
Explore our Key Issues on Health Care
- Air Quality
- Border Security and Immigration
- Children's Health and Safety
- Drug Misuse
- Elder Abuse
- Health Care Quality
- Health Information Technology
- Improper Payments
- Improving Federal Programs that Serve Tribes and Their Members - High Risk Issue
- Managing Risks and Improving VA Health Care
- Medicaid - High Risk Issue
- Medical Product Oversight - High Risk Issue
- Medicare - High Risk Issue
- Prescription Drug Spending
- Supports and Services for Transitioning Veterans
- Toxic Chemicals - High Risk Issue
- Tribal and Native American Issues
- VA and DOD Health Care Management
- VA and DOD Patient Care
- Women and Gender in Public Policy
Explore our other Key Issues here
